Drug glossary Drug

Hsk42360-na

A drug being studied in colorectal cancer trials. It appears in 2 clinical trials.

See its trials
United States No data
European Union No data
Spain No data

What it is

HSK42360-Na is an investigational medication currently being studied in clinical trials. It is being evaluated as a potential treatment for solid tumors, specifically those with a BRAF V600 mutation. The trials are in the early phase (Phase 1), focusing on determining the safe dosage and how the drug is processed by the body (pharmacokinetics) and its effects on the body (pharmacodynamics). It is taken orally. This drug is not yet approved for use in colorectal cancer or any other condition.

How it works

HSK42360-Na is being investigated for its potential activity against tumors that have a specific genetic change called a BRAF V600 mutation. The exact way HSK42360-Na works is still being studied, but it is designed to target processes within cancer cells. The specific molecular target is being characterized in clinical trials.

Common side effects

Because HSK42360-Na is in Phase 1 clinical trialsThe full range of potential side effects is still being evaluated. Safety and tolerability are the primary focus of these early studies. Information about common or specific side effects is not yet available from these trials

Not all are listed, and everyone experiences them differently. If you notice any, tell your care team.